SCHEMBL1900144

SCHEMBL1900144

CSc1nc(Cl)c2c(C)c[nH]c2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 7/20 0.42
CHUK O15111 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
KCNH2 Q12809 2/20 0.33
PPARG P37231 1/20 0.32
LMNA P02545 1/20 0.32
HPGD P15428 1/20 0.32
CCNT1 O60563 1/20 0.31
CCNA2 P20248 1/20 0.31
CDK2 P24941 1/20 0.31
CDK9 P50750 1/20 0.31
CCNA1 P78396 1/20 0.31
CDK5 Q00535 1/20 0.31
CDK5R1 Q15078 1/20 0.31
KDM4E B2RXH2 1/20 0.31
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29589353 0.83 CHEK1 (0.49) HSP90AB1CHUKCYP1A2CYP2C9CYP2C19
SCHEMBL19731488 0.83 CHEK1 (0.49) HSP90AB1CHUKCYP1A2CYP2C9CYP2C19
SCHEMBL14421840 0.83 HSP90AB1 (0.38) HSP90AB1CHUKCYP1A2CYP2C9CYP2C19
SCHEMBL1014720 0.79 CHUK (0.38) HSP90AB1CHUK
SCHEMBL31095475 0.79 CHUK (0.38) HSP90AB1CHUK
SCHEMBL20182173 0.79 PDK2 (0.45) HSP90AB1CHUKKMT2ALMNACDK9
SCHEMBL14421907 0.79 CHUK (0.61) HSP90AB1CHUKCYP1A2CYP2C9CYP2C19
SCHEMBL7244574 0.77 POLB (0.35) HSP90AB1CHUKKMT2AKCNH2PPARG
SCHEMBL12161103 0.77 KMT2A (0.35) HSP90AB1CHUKKMT2APPARGCDK2
SCHEMBL1738453 0.76 CHUK (0.58) HSP90AB1CHUKCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3486244-A1 NEW COMPOUND HAVING FGFR INHIBITORY ACTIVITY AND PREPARATION AND APPLICATION THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2019-05-22 EP disclosed
WO-2017215485-A1 NEW COMPOUND HAVING FGFR INHIBITORY ACTIVITY AND PREPARATION AND APPLICATION THEREOF 中国科学院上海药物研究所 2017-12-21 WO disclosed
US-20110124715-A1 Antiviral Oligonucleotides Having a Conserved G4 Core Sequence HANECAK RONNIE C 2011-05-26 US disclosed
US-20070015723-A1 Antiviral oligonucleotides having a conserved G4 core sequence ISIS PHARMACEUTICALS, INC. 2007-01-18 US disclosed
EP-0672193-B1 USE OF OLIGONUCLEOTIDES HAVING A CONSERVED G 4 CORE SEQUENCE FOR THE PREPARATION OF A MEDICAMENT ISIS PHARMACEUTICALS INC (US) 2002-08-14 EP disclosed
EP-1016715-A1 Oligonucleotides having a conserved G4 core sequence ISIS PHARMACEUTICALS, INC. (US) 2000-07-05 EP disclosed
EP-0691980-B1 7-DEAZAPURINE MODIFIED OLIGONUCLEOTIDES SANOFI SA (FR) 1997-06-04 EP disclosed
EP-0691980-A1 7-DEAZAPURINE MODIFIED OLIGONUCLEOTIDES STERLING WINTHROP INC (US) 1996-01-17 EP disclosed
EP-0672193-A1 OLIGONUCLEOTIDES HAVING A CONSERVED G 4? CORE SEQUENCE ISIS PHARMACEUTICALS, INC. (US) 1995-09-20 EP disclosed
WO-1994022892-A1 7-DEAZAPURINE MODIFIED OLIGONUCLEOTIDES STERLING WINTHROP INC. (US) 1994-10-13 WO disclosed
WO-1994008053-A1 OLIGONUCLEOTIDES HAVING A CONSERVED G4 CORE SEQUENCE ISIS PHARMACEUTICALS, INC. (US) 1994-04-14 WO disclosed